The first patient has been enrolled in a two-stage phase 2 study of D-4517.2 for the treatment of wet age-related macular degeneration or diabetic macular edema, according to a press release from Ashvattha Therapeutics.
The clinical study will evaluate the safety and efficacy of the subcutaneously administered treatment candidate, a hydroxyl dendrimer therapeutic with potent anti-VEGF activity, at different dose levels compared with intravitreal aflibercept.
The first stage of the study will include 30 participants with wet AMD or DME who will be monitored for adverse events for up to (Read more...)